Pasar al contenido principal

RETOS EN LA PREVENCION DE LA DIABETES MATERNA TRAS LA DIABETES GESTACIONAL: DESCIFRANDO LA REMODELACION MOLECULAR Y FUNCIONAL DEL PANCREAS ENDOCRINO EN EL EMBARAZO Y POSPARTO.

PID2023-146795OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2023
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD MIGUEL HERNANDEZ DE ELCHE

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

RUA. Repositorio Institucional de la Universidad de Alicante
Publicación Otros (Other)

Increased TGF-β/Activin-Smad2 signaling is associated with pancreatic β-cell dysfunction and glucose intolerance in gestational diabetes mellitus

  • Boronat-Belda, Talía
  • Ferrero, Hilda
  • Soriano, Sergi
  • Ribes-García, Elena
  • Betoret-Gustems, Rubén
  • Martínez-Bañón, Daniel
  • Serrano-Selva, Mónica
  • Martinez-Pinna, Juan
  • Nadal, Ángel
  • Quesada, Iván
  • Alonso Magdalena, Paloma
  • Ferrero, Hilda|||/items/b14c3b70-6622-414b-85e8-332ff8cd0de7
  • Soriano, Sergi|||/items/8e3d590c-5b30-415a-93aa-bf5d4506efe4
  • Martinez-Pinna, Juan|||/items/17fe7946-bb18-45cf-bd71-482acc1cec7b
Background: Gestational diabetes mellitus (GDM) is the most common metabolic disease during pregnancy and increases the prevalence of type 2 diabetes in both mothers and children. GDM management provides an opportunity to prevent and lower the global burden of diabetes across life. Molecular mechanisms underlying GDM are not completely understood. In this study, we explore the role of transforming growth factor beta (TGF-β) signaling in GDM, as this pathway reportedly affects pancreatic β-cell development, function, and proliferation. Methods: We developed a GDM animal model. Serum circulating levels of TGF-β family ligands were measured in mice and human GDM. Pancreatic TGF-β signaling was investigated via gene and protein expression. Results: Our GDM animal model recapitulates the main pathophysiological features of human GDM, including glucose intolerance, decreased insulin sensitivity and pancreatic β-cell malfunction. Islets from GDM mice showed impaired insulin secretion and content, altered ion channel activity, and decreased β-cell replication rate. This was accompanied by increased Smad2 signaling activation. Elevated serum activin-A and inhibin levels were found in mice and human GDM, suggesting their role as upstream signaling transducers of pancreatic Smad2 activation. Pharmacological inhibition of TGF-β/Activin-Smad2 signaling in mouse pancreatic islets resulted in improved pancreatic β-cell function and regeneration capacity. Conclusions: Our data suggest that disruption of the pancreatic Smad2 pathway plays a critical role in the pathogenesis of GDM, contributing to abnormal glucose homeostasis and inadequate insulin secretion. Attenuation of this signaling pathway may represent a putative therapeutic target for GDM.
RUA. Repositorio Institucional de la Universidad de Alicante
Publicación Otros (Other)

Aging Affects Pancreatic α-Cell Function and Promotes Hyperglucagonemia: Implications in Age-Associated Diabetes

  • Tudurí, Eva|||/items/ed03c763-6d0f-4b5a-a720-80238ac8cc4e
  • Almagro, Lucía
  • Ojeda-Rodríguez, Ana
  • Pascua-Maestro, Raquel
  • Brunetta, Henver S.
  • Soriano, Sergi|||/items/8e3d590c-5b30-415a-93aa-bf5d4506efe4
  • López-Moreno, Alejandro
  • Boronat-Belda, Talía
  • Velasco-Avilés, Sergio
  • da Silva Junior, Joel Alves
  • Castellano-Muñoz, Manuel
  • Rafacho, Alex
  • Cozar-Castellano, Irene
  • Nadal, Ángel
  • Alonso Magdalena, Paloma
  • Merino, Beatriz
  • Lopez-Miranda, Jose
  • Quesada, Iván
Aging is a major risk factor in the development of type 2 diabetes mellitus (T2DM). With age, pancreatic β-cells undergo functional and cell identity changes that can compromise insulin secretion, thereby contributing to impaired glucose tolerance and T2DM. However, glucose homeostasis also depends on pancreatic α-cells. Excessive plasma glucagon levels, along with impaired regulation of α-cell secretion, are involved in the pathophysiology of T2DM. Despite their importance, the effects of aging on α-cells have been overlooked. In the present study, we analyzed pancreatic α-cells in aged mice with normal insulin sensitivity and in those with peripheral insulin resistance. Regardless of insulin sensitivity, aged mice exhibited hyperglucagonemia and increased glucagon release. Ex vivo, these alterations were associated with increased α-cell mass, higher glucagon content, impaired suppression of glucagon secretion, and endoplasmic reticulum stress. Furthermore, aged mice showed remodeling of islet cellular composition and changes in the spatial organization of α-cells within the islet. Additionally, moderate alterations in α-cell identity were noted. While most of these alterations were already present in aged mice with normal insulin sensitivity, they were generally more pronounced with insulin resistance. Examination of the CORDIOPREV clinical study revealed the presence of hyperglucagonemia in older adults with insulin resistance. Additionally, an increased risk of developing T2DM was also found in older people with higher plasma glucagon levels. The findings described here indicate that aging affects the biology of α-cells and glucagon, positioning them as active players in impaired glucose tolerance and diabetes associated with aging.
RUA. Repositorio Institucional de la Universidad de Alicante
Publicación Otros (Other)

Inhibition of glucagon secretion from pancreatic α-cells by the bile acid TUDCA involves a S1PR2-PI3K pathway

  • da Silva Junior, Joel Alves
  • Vettorazzi, Jean Franciesco
  • Soriano, Sergi
  • Bru-Tarí, Eva
  • Boronat-Belda, Talía
  • Castellano-Muñoz, Manuel
  • Borck, Patricia Cristine
  • Ribeiro, Rosane Aparecida
  • Soares, Gabriela Moreira
  • Lubaczeuski, Camila
  • Boschero, Antônio Carlos
  • Marroquí, Laura
  • Nadal, Ángel
  • Alonso Magdalena, Paloma
  • Quesada, Iván
  • Carneiro, Everardo Magalhães
  • Soriano, Sergi|||/items/8e3d590c-5b30-415a-93aa-bf5d4506efe4
The global prevalence of type 2 diabetes (T2D) continues to rise, and predictions indicate alarming records in coming decades. Although pancreatic β-cell dysfunction and insulin resistance are key factors in the etiology of T2D, the impairment of α-cells has been also implicated. Hyperglucagonemia and altered suppression of glucagon release can be frequently found in individuals with T2D, contributing to hyperglycemia. Bile acids have emerged as novel signaling molecules that regulate metabolism. A wealth of evidence shows that oral treatment with the bile acid TUDCA has therapeutic benefits in T2D, primarily by improving both insulin release from β-cells and insulin sensitivity in peripheral tissues. However, it is unknown whether TUDCA could affect other processes involved in the control of glucose metabolism. Here, we show that acute administration of TUDCA exerts a glucagonstatic action on mouse pancreatic islets and glucagon-releasing αTC1-9 cells. Pharmacological and/or molecular inhibition of the sphingosine-1-phosphate receptor 2 (S1PR2) and the PI3K pathway blunted the TUDCA effect on glucagon release. Additionally, TUDCA increased the activity of ATP-sensitive K+ (KATP) channels, decreased action currents and inhibited Ca2+ signaling in α-cells without directly affecting the exocytotic process. Glucose-induced suppression of glucagon secretion was found to be compromised under hyperglycemic conditions, yet TUDCA was able to inhibit α-cell function, highlighting its glucagonstatic effect in a pathological context. Collectively, these findings suggest that TUDCA-induced inhibition of glucagon secretion involves the opening of α-cell KATP channels and activation of the S1PR2/PI3K pathway, expanding the repertoire of potential therapeutic benefits of TUDCA in diabetes treatment.